7 completed, 2 recruiting, 2 unknown, 1 active not recruiting. 5 Not applicable, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 5 | Completed 2, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 4, Recruiting 1 |
| Phase 3 | 1 | Terminated 1 |
Follow TB: new trials by email Literature Review of TB trials Research Report on TB
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TB Stigma in the UK: Patients Experiences and Everyday Responses TB, Tuberculosis | Not yet recruiting | Bournemouth University | 20 | 2026-09-01 | 2026-05-27 | |
| Parent Study Name: Pulmonary Rehabilitation to Reduce Post-Tuberculosis Morbidity (TB Pure) 8 week (short arm) Intervention - pulmonary rehabilitation, 24 week (long arm) Intervention - pulmonary rehabilitation - TB - Tuberculosis, TB | Not applicable | Recruiting | Johns Hopkins University | 690 | 2026-03-18 | 2026-03-27 |
| Pharmacokinetic Study of Sudapyridine（WX-081）in Healthy Chinese Subjects [U-14C] WX-081 - TB | Phase 1 | Recruiting | Shanghai Jiatan Pharmatech Co., Ltd | 10 | 2024-09-04 | 2024-11-22 |
| Evaluation of the Truenat™MTB Plus/COVID-19 Test for TB (Tuberculosis) and COVID-19 (SARS-CoV2) Truenat™ MTB Plus/COVID-19 - TB, COVID-19 | Completed | Foundation for Innovative New Diagnostics, Switzerland | 1984 | 2022-08-30 | 2026-09-04 | |
| Leveraging mHealth to Enable and Adapt CHW Strategies to Improve TB/HIV Patient Outcomes in SA CHW mHealth patient intervention for trigger escalation - Adherence, Patient, TB | Not applicable | Active not recruiting | Johns Hopkins University | 62 | 2022-03-10 | 2026-01-29 |
| Impact of a Pharmacist-led Patient-centred Care Intervention Along With Text-Message Reminders, on the Management of Newly Diagnosed Tubercular Patients: a Protocol for a Randomized Controlled Trial'. New management mode - Pulmonary TB, TB | Not applicable | Completed | Xi'an Jiaotong University | 450 | 2020-09-01 | 2022-06-29 |
| Cytometric Immunodiagnostics of Latent Tuberculosis Infection (LTBI) Blood draw - LTBI, BCG Vaccination Reaction | Unknown | Thomayer University Hospital | 120 | 2020-01-02 | 2020-12-17 | |
| Childhood Acute Illness and Nutrition Network Malnutrition, Pneumonia | Unknown | University of Oxford | 4335 | 2016-11-30 | 2020-05-20 | |
| Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients levofloxacin, moxifloxacin - TB | Phase 3 | Terminated | Seoul National University Hospital | 182 | 2010-03-01 | 2012-11-27 |
| A Study of MVA85A, in Asymptomatic Volunteers Infected With TB, HIV or Both MVA 85A - HIV Infections, TB | Phase 1 | Completed | University of Oxford | 48 | 2007-07-01 | 2011-03-28 |
| Comparison of the Quantiferon®-TB GOLD (in Tube) Assay With Tuberculin Skin Testing for Detecting Latent Tuberculosis Infection in Patients With Chronic Liver Disease Being Evaluated for or Awaiting Liver Transplantation collection of blood sample - Chronic Liver Disease, TB | Not applicable | Withdrawn | University of Pittsburgh | 2007-01-01 | 2020-05-07 | |
| Safety, Immunogenicity, and Impact of MVA85A, on the Immunogenicity of the EPI Vaccines MVA 85A - TB | Phase 1 | Completed | University of Oxford | 214 | 2006-10-01 | 2010-02-09 |
| Study of the Safety and Immunogenicity of Bacille Calmette Guerin (BCG) Vaccine BCG - TB | Phase 1 | Completed | University of Oxford | 11 | 2004-02-01 | 2008-04-07 |
| A Study of the Immunogenicity of BCG, Delivered Intradermally in Healthy Volunteers BCG (SSI Strain) - TB | Not applicable | Completed | University of Oxford | 10 | 2003-03-01 | 2007-05-31 |
| A Study of the Immunogenicity of M. Bovis BCG, Delivered Intradermally in Healthy Volunteers BCG - TB | Phase 1 | Completed | University of Oxford | 11 | 2001-11-01 | 2007-05-31 |
Tuberculosis (4) · Acquired Immunodeficiency Syndrome (3) · Tuberculosis, Pulmonary (2) · Bacteremia (1) · COVID-19 (1) · Diarrhea (1) · HIV Infections (1) · Intestinal Diseases (1) · Latent Tuberculosis (1) · Malnutrition (1) · Patient Compliance (1) · Pneumonia (1) · Sepsis (1) · Social Stigma (1) · Tuberculosis, Multidrug-Resistant (1)
Infections (10) · Bacterial Infections (8) · Bacterial Infections and Mycoses (8) · Actinomycetales Infections (7) · Gram-Positive Bacterial Infections (7) · Mycobacterium Infections (7) · Lung Diseases (4) · RNA Virus Infections (4) · Respiratory Tract Diseases (4) · Respiratory Tract Infections (4) · Virus Diseases (4) · Blood-Borne Infections (3) · Communicable Diseases (3) · Genital Diseases (3) · Immune System Diseases (3)
MVA 85A (2) · MVA Pfs25-IMX313 malaria vaccine (2) · Blood Specimen Collection (1) · Levofloxacin (1) · Moxifloxacin (1) · Pharmaceutical Services (1) · sudapyridine (1)
University of Oxford (6) · Johns Hopkins University (2) · Bournemouth University (1) · Foundation for Innovative New Diagnostics, Switzerland (1) · Seoul National University Hospital (1) · Shanghai Jiatan Pharmatech Co., Ltd (1) · Thomayer University Hospital (1) · University of Pittsburgh (1) · Xi'an Jiaotong University (1)
United Kingdom (4) · Pakistan (2) · Uganda (2) · United States (2) · Bangladesh (1) · China (1) · Czechia (1) · India (1) · Kenya (1) · Malawi (1) · South Africa (1) · South Korea (1) · The Gambia (1)
Helen McShane (3) · Helen I McShane (2) · Akshay Gupte, PhD MBBS MSPH (1) · Amjad Khan, Phd (1) · David L Paterson, MD (1) · Fernanda Silveira, MD (1) · Jae-Joon Yim, MD (1) · James A Berkley, MBBS, FRCPCH (1) · Jason E Farley, PhD, MPH (1) · Jonathan Golub, PhD MPH (1) · Judd L Wilson, MD, MPH (1) · Yu Fang, Phd (1)
PMID 15502839, PMID 17957238, PMID 19529780, PMID 22281831, PMID 23927582, PMID 25466778, PMID 26871879, PMID 31061058, PMID 36123771, PMID 36415883, PMID 38356837, PMID 40122135, PMID 42247451
R01AI169588 (1)